APA (7th ed.) Citation

EM, H., A, K., N, A., B, F., Y, Y., A, P., . . . AA, J. (2024). Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer, 130(7), 1061. https://doi.org/10.1002/cncr.35126

Chicago Style (17th ed.) Citation

EM, Hinchcliff, et al. "Randomized Phase 2 Trial of Tremelimumab and Durvalumab in Combination Versus Sequentially in Recurrent Platinum-resistant Ovarian Cancer." Cancer 130, no. 7 (2024): 1061. https://doi.org/10.1002/cncr.35126.

MLA (9th ed.) Citation

EM, Hinchcliff, et al. "Randomized Phase 2 Trial of Tremelimumab and Durvalumab in Combination Versus Sequentially in Recurrent Platinum-resistant Ovarian Cancer." Cancer, vol. 130, no. 7, 2024, p. 1061, https://doi.org/10.1002/cncr.35126.